Q2 saw 5% sales growth and strong momentum in Specialty medicines and Vaccines, with updated 2026 guidance reflecting higher sales and operating profit expectations. The Accelerate Growth program will fund R&D and late-stage pipeline expansion, supported by robust cash flow and disciplined capital allocation.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.